KEYNOTE-119: A randomized phase III study of single-agent pembrolizumab (MK-3475) vs single-agent chemotherapy per physician's choice for metastatic triple-negative breast cancer (mTNBC).
Winer E, Dang T, Karantza V, Su S. KEYNOTE-119: A randomized phase III study of single-agent pembrolizumab (MK-3475) vs single-agent chemotherapy per physician's choice for metastatic triple-negative breast cancer (mTNBC). Journal Of Clinical Oncology 2016, 34: tps1102-tps1102. DOI: 10.1200/jco.2016.34.15_suppl.tps1102.Peer-Reviewed Original Research